Search -

Displaying 1 - 20 of 29

Sort: Relevancy | Date

Presentation TCT 2025

TCT 520: Revascularization in HBR Made Safer: Leveraging Sirolimus-DCB and SAPT

Presenter: Victor Alfonso Jimenez Diaz

October 28, 2025

Presentation TCT 2024

TCT 956: Validation of the VARC-HBR Criteria in TAVI Patients on Oral Anticoagulation

Presenter: Daniel Overduin

October 30, 2024

Presentation TCT 2024

TCT 242: Prospective Validation of the ARC-HBR, PRECISE-DAPT, and PARIS Risk Prediction Model in the All-Comer PIONEER IV Trial

Presenter: TsungYing Tsai

October 28, 2024

Presentation TCT 2024

From ARC-HBR and PRECISE-DAPT to PRECISE-2: Development and Validation of a Novel Universal Bleeding Risk Score

Presenter: Marco Valgimigli

October 27, 2024

Presentation TCT 2023

The Primary Endpoint Results from the COMPARE 60/80 HBR Trial: A Randomized Controlled Multi-Center Trial Comparing Ultrathin With Thin Strut Stents in High Bleeding Risk Patients With an Abbreviated DAPT Duration

Presenter: Pieter Smits

October 25, 2023

Presentation TCT 2022

Coronary DCB in HBR Patients: An Alternative to DES?

Presenter: Tuomas Rissanen

September 18, 2022

Presentation TCT 2022

Does It Matter What Stent I Use in a HBR Patient?

Presenter: Pieter Smits

September 18, 2022

Presentation TCT 2021

Latest Evidence on Short DAPT & HBR Patients

Presenter: Rafael Cavalcante

November 06, 2021

Presentation TCT 2021

Latest HBR Clinical Evidence

Presenter: Marco Valgimigli

November 04, 2021

Presentation TCT 2020

The XIENCE Short DAPT Program: XIENCE 90/28 - Evaluating the Safety of 3-month and 1-month DAPT in HBR Patients

Presenter: Roxana Mehran

October 15, 2020

Presentation TCT 2020

TCT 062: Short Term Dual Anti-Platelet Therapy Followed by P2Y12 Monotherapy After Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Control Trials

Presenter: Mohammad Saud Khan

October 14, 2020

Presentation TCT 2020

TCT 066: Ischemic and Bleeding Outcomes in Patients With vs. Without Atrial Fibrillation: Analysis From the Onyx ONE Month DAPT Program

Presenter: Sanjeevan Pasupati

October 14, 2020

Presentation TCT 2020

TCT 056: Prolonged Dual Antiplatelet Therapy in Patients With or Without Prior Myocardial Infarction: An Updated Systematic Review and Meta-Analysis

Presenter: Mauro Chiarito

October 14, 2020

Presentation TCT 2020

TCT 065: Cangrelor Use Patterns and Transition to Oral P2Y12 Inhibitors Among Patients With Myocardial Infarction: Early Results From the Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes (CAMEO) Registry

Presenter: Jennifer Rymer

October 14, 2020

Presentation TCT 2020

TCT 060: Contribution of ESC DAPT Guideline-Endorsed High Thrombotic Risk Features to Long-Term Clinical Outcomes Among Patients With and Without High Bleeding Risk After PCI

Presenter: Hao-Yu Wang

October 14, 2020

Presentation TCT 2020

TCT 057: Clinical Outcomes According to Lesion Complexity in High Bleeding Risk Patients Treated With 1-Month Dual Antiplatelet Therapy Following PCI: Analysis From the Onyx ONE Clear Study

Presenter: David Kandzari

October 14, 2020

Presentation TCT 2020

TCT 055: Short Duration of Dual Antiplatelet Therapy After PCI With DES: An Updated Meta-Analysis of Randomized Controlled Trials.

Presenter: Ahmed Elzanaty

October 14, 2020

Presentation TCT 2020

TCT 067: Antithrombotic Treatment Strategies in Patients Older than 75 Years With Atrial Fibrillation After Percutaneous Coronary Intervention With Drug-Eluting Stents. The PACO-PCI Registry

Presenter: Jose de la Torre Hernandez

October 14, 2020

Presentation TCT 2020

TCT 059: Meta-Analysis of Bleeding, MACE and Mortality in Clinical Trials of Time-Constrained Dual-Antiplatelet Therapy After PCI

Presenter: Jennifer Ramsay

October 14, 2020

Presentation TCT 2020

TCT 058: Evaluation of Antithrombotic Strategies Before and After the First Month of Therapy: Landmark Analysis of the RE-DUAL PCI Trial

Presenter: Benjamin Peterson

October 14, 2020

Advertisement

TCT 520: Revascularization in HBR Made Safer: Leveraging Sirolimus-DCB and SAPT

TCT 956: Validation of the VARC-HBR Criteria in TAVI Patients on Oral Anticoagulation

TCT 242: Prospective Validation of the ARC-HBR, PRECISE-DAPT, and PARIS Risk Prediction Model in the All-Comer PIONEER IV Trial

From ARC-HBR and PRECISE-DAPT to PRECISE-2: Development and Validation of a Novel Universal Bleeding Risk Score

The Primary Endpoint Results from the COMPARE 60/80 HBR Trial: A Randomized Controlled Multi-Center Trial Comparing Ultrathin With Thin Strut Stents in High Bleeding Risk Patients With an Abbreviated DAPT Duration

Coronary DCB in HBR Patients: An Alternative to DES?

Does It Matter What Stent I Use in a HBR Patient?

Latest Evidence on Short DAPT & HBR Patients

Latest HBR Clinical Evidence

The XIENCE Short DAPT Program: XIENCE 90/28 - Evaluating the Safety of 3-month and 1-month DAPT in HBR Patients

TCT 062: Short Term Dual Anti-Platelet Therapy Followed by P2Y12 Monotherapy After Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Control Trials

TCT 066: Ischemic and Bleeding Outcomes in Patients With vs. Without Atrial Fibrillation: Analysis From the Onyx ONE Month DAPT Program

TCT 056: Prolonged Dual Antiplatelet Therapy in Patients With or Without Prior Myocardial Infarction: An Updated Systematic Review and Meta-Analysis

TCT 065: Cangrelor Use Patterns and Transition to Oral P2Y12 Inhibitors Among Patients With Myocardial Infarction: Early Results From the Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes (CAMEO) Registry

TCT 060: Contribution of ESC DAPT Guideline-Endorsed High Thrombotic Risk Features to Long-Term Clinical Outcomes Among Patients With and Without High Bleeding Risk After PCI

TCT 057: Clinical Outcomes According to Lesion Complexity in High Bleeding Risk Patients Treated With 1-Month Dual Antiplatelet Therapy Following PCI: Analysis From the Onyx ONE Clear Study

TCT 055: Short Duration of Dual Antiplatelet Therapy After PCI With DES: An Updated Meta-Analysis of Randomized Controlled Trials.

TCT 067: Antithrombotic Treatment Strategies in Patients Older than 75 Years With Atrial Fibrillation After Percutaneous Coronary Intervention With Drug-Eluting Stents. The PACO-PCI Registry

TCT 059: Meta-Analysis of Bleeding, MACE and Mortality in Clinical Trials of Time-Constrained Dual-Antiplatelet Therapy After PCI

TCT 058: Evaluation of Antithrombotic Strategies Before and After the First Month of Therapy: Landmark Analysis of the RE-DUAL PCI Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content